Abdulla Majid-Moosa, DO
Critical Care Medicine · Baton Rouge, LANPI 1558628859
Payments from drug & device makers
Across 480 payments — averaging $420.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$196K
- Pulmonx Corporation$3K
- GSK$1K
- Sanofi$511
- Merit Medical Systems Inc$461
- Boehringer Ingelheim$147
- plus $1K from 27 others
What the payments were for
- Consulting fees$8000%
- Speaking & faculty fees$28,95014%
- Travel & lodging$28,12114%
- Food & beverage$15,9648%
- Education$128,20063%
- Gifts$220%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 286 | $195,537 |
| Pulmonx Corporation | 14 | $2,725 |
| GSK | 87 | $1,339 |
| Sanofi | 15 | $511 |
| Merit Medical Systems Inc | 3 | $461 |
| Boehringer Ingelheim | 8 | $147 |
| AstraZeneca | 8 | $136 |
| Merck | 5 | $109 |
| Johnson & Johnson | 5 | $108 |
| Mylan Specialty L.p. | 4 | $102 |
| Actelion Pharmaceuticals US, Inc. | 3 | $85 |
| United Therapeutics Corporation | 3 | $70 |
| Electromed, Inc. | 9 | $65 |
| E.r. Squibb & Sons, L.L.C. | 3 | $52 |
| Steris Corporation | 1 | $51 |
| La Jolla Pharmaceutical Company | 3 | $49 |
| Paratek Pharmaceuticals, Inc. | 3 | $46 |
| Viatris Specialty LLC | 2 | $43 |
| UCB, Inc. | 3 | $40 |
| Atricure, Inc. | 2 | $38 |
| Regeneron Healthcare Solutions, Inc. | 1 | $35 |
| Olympus America Inc. | 1 | $33 |
| Partner Therapeutics, Inc. | 1 | $33 |
| Tactile Systems Technology Inc | 1 | $32 |
| ANI Pharmaceuticals, Inc. | 1 | $31 |
| Ultragenyx Pharmaceutical Inc. | 1 | $30 |
| AbbVie | 1 | $29 |
| Mallinckrodt Enterprises LLC | 1 | $28 |
| Innovation Technologies Inc | 1 | $23 |
| Grifols USA, LLC | 1 | $22 |
| Davol Inc. | 1 | $19 |
| Chiesi USA, Inc. | 1 | $16 |
| Pfizer | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$202,057 in reported general payments places this provider in the 95th percentile of 72 critical care medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 11 | $142,962 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 152 | $121,181 |
| Spiriva RespimatTiotropium Bromide | 12 | $14,592 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 18 | $14,111 |
| Spiriva HandihalerTiotropium Bromide | 14 | $12,768 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $7,673 |
| Varenicline Tartrate | 30 | $7,073 |
| SymbicortBudesonide/Formoterol Fumarate | 20 | $6,315 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $5,514 |
| Arnuity ElliptaFluticasone Furoate | 16 | $4,074 |
| Wixela InhubFluticasone Propion/Salmeterol | 15 | $2,088 |
| Roflumilast | 25 | $2,012 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 65 | $2,006 |
| Mycophenolate Mofetil | 14 | $1,212 |
| Ethambutol Hcl | 22 | $947 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat | $147 | $157,55423 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $1,339 | $138,441194 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $136 | $20,42638 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 72 critical care medicine providers in Louisiana.
Other critical care medicine in Baton Rouge
- James VermaelenBaton Rouge$27K
- Ahmad SharayahBaton Rouge$12K
- Ronald FieldsBaton Rouge$11K
- Merissa BraudBaton Rouge$8K
- Mostafa AboubakrBaton Rouge$6K
- James FordBaton Rouge$6K
- Vincent ValentineBaton Rouge$6K
- Daniel ReesBaton Rouge$4K
- Owen StellBaton Rouge$3K
- Dena LandryBaton Rouge$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.